** GILD reported that the Antiviral Drugs Advisory Committee of the FDA has voted 13 to 1 in support of approval of the Quad, a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for the treatment of HIV-1 infection in treatment-naïve adults. The recommendations of the Advisory Committee are not binding, but will be considered by FDA as the agency completes its review of GILD’s New Drug Application (NDA) of the Quad.GILD submitted the NDA on October 27, 2011 and FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of August 27, 2012.